AD/PD 2107 Draws Record Number of Scientists To Vienna

Vienna, Austria

Held in the historic Austrian capital, the 13th AD/PD conference reflected a rapidly growing field. The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention. There were no show-stopping announcements, but researchers noted biomarker advances on both the PET and CSF front, as well as a flourishing variety of basic science talks on tau, TREM2, epigenetics, and other topics. On the clinical side, one company touted a successful Phase 3 trial for transcranial magnetic stimulation to treat Alzheimer’s, but potential disease-modifying therapies for both AD and PD remain in development.

  1. Anti-Amyloid Drug Pipeline Shows No Sign of Drying Up
  2. Non-Amyloid Treatments: Inflammation, Epigenetics, Regeneration
  3. α-Synuclein Antibodies Enter Phase 2, Sans Biomarker

ARUK Roundtable: Where Now for Alzheimer's Disease Research?

London, England

At an expert meeting convened by Alzheimer’s Research UK, scientists from Eli Lilly shared Aβ biomarker data from the Expedition 3 trial with colleagues in academia and pharma. Reading the trial’s tea leaves together, the group felt that solanezumab entering the brain from the blood might have brought Aβ along for the ride, confounding CSF biomarker measurements. To boot, the trial appears to have enrolled participants with more brain amyloid than its predecessors. Given the weakness of the biomarker results, scientists, despite a day of deliberation, were left with merely a gut feeling that the hint of a cognitive benefit in the trial was probably real, if too small. A lively brainstorm session of where AD translational research should go next concluded the day. Read Gabrielle Strobel’s two-part story.

View all 2 articles on this conference

Clinical Trials on Alzheimer's Disease

San Diego, California

If the setback of the Expedition 3 study of solanezumab set their mood in the beginning, attendees at the 2016 Clinical Trials on Alzheimer’s Disease conference soon bucked up and voiced renewed determination to tackle this illness. Many took positive secondary outcomes and trends in this Phase 3 trial as a sign that this or more potent anti-amyloid drugs given earlier will make a bigger dent in the disease process. Short of major surprises, the meeting reaffirmed the sense that AD will only be slowed by deploying potent drugs at the right target (probably more than one), with the right dose, and certainly at the right time.      

View all 5 articles on this conference

Society for Neuroscience

San Diego, California

When more than 30,000 registrants gathered at the San Diego Convention Center for the Society for Neuroscience annual meeting November 12-16, they exchanged their latest data on the basic science on Alzheimer’s disease. Topics ran the gamut from protein propagation and inflammation to the hunt for plasma biomarkers and potential therapeutics. Alzforum reporter Madolyn Rogers brings you highlights.

View all 7 articles on this conference

Kloster Seeon meeting on BACE proteases in health and disease

Seeon-Seebruck, Bavaria, Germany

Since the first Kloster Seeon meeting on β-secretases in 2013, a handful of BACE inhibitors have entered clinical trials and researchers have learned more about what these proteases do in development and adulthood. What’s the status of the field in the fall of 2016? Check out our coverage of the 2nd Kloster Seeon meeting. Highlights include conditional BACE1 knockouts, updates on non-APP substrates cleaved by BACE, news about BACE’s role in dystrophic neurites, assays to measure off-target effects and—finally—the arrival of BACE1-selective inhibitors.

View all 5 articles on this conference

International Conference on Frontotemporal Dementias 2016

Munich, Germany

As research on frontotemporal dementia gathers steam, the international conference hosted its largest gathering ever last month in Munich, Germany. More than 750 researchers shared their latest data on basic science, genetics, and clinical outcome measures. Biomarkers dominated the meeting, as the field prepares for therapy trials by seeking better ways to track pathology in living people. The few trials that have been done thus far, without specific biomarkers, have largely been a bust. 

View all 6 articles on this conference

Alzheimer's Association International Conference 2016

Toronto, Canada

Held July 22 to 28 in Toronto, the Alzheimer’s Association International Conference showcased a field in transformation. At the clinical level, groups from Europe, North America, and Japan are attempting to coalesce around new ways to recruit preclinical populations for large observational and trial platforms for late-onset AD, while the smaller but more established DIAN initiative is growing into a worldwide movement. At the biological level, research is set to expand thanks to funding increasing in response to national plans. Health economics research is pressing in. Topically, tau ruled the roost, though genetics, vascular contributions to dementia, and efforts to define ever-earlier stages of the decades-long disease continuum advanced, as well. On the clinical trials front, the only Phase 3 study appears to have been largely a bust, while some Phase 1 presentations of new antibodies, BACE inhibitors, and a small-molecule tau modifier drew quiet praise. 

View all 18 articles on this conference